Walvax Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Walvax Biotechnology şirketinin toplam hissedar öz sermayesi CN¥11.7B ve toplam borcu CN¥712.0M olup, bu da borç-öz sermaye oranını 6.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥15.0B ve CN¥3.3B dir. Walvax Biotechnology 'in FAVÖK'ü CN¥348.4M faiz karşılama oranı -5.5 dur. Şirketin CN¥3.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

6.1%

Borç/özkaynak oranı

CN¥711.96m

Borç

Faiz karşılama oranı	-5.5x
Nakit	CN¥3.62b
Eşitlik	CN¥11.73b
Toplam yükümlülükler	CN¥3.27b
Toplam varlıklar	CN¥15.00b

Son finansal sağlık güncellemeleri

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

Recent updates

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Sep 24

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300142 'nin kısa vadeli varlıkları ( CN¥7.4B ) kısa vadeli yükümlülüklerini ( CN¥2.4B ) aşıyor.

Uzun Vadeli Yükümlülükler: 300142 şirketinin kısa vadeli varlıkları ( CN¥7.4B ) uzun vadeli yükümlülüklerini ( CN¥883.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300142 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 300142 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 6.1% seviyesine yükseldi.

Borç Kapsamı: 300142 'nin borcu işletme nakit akışı ( 116.9% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 300142 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Walvax Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Recent updates

Consensus revenue estimates fall by 11%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Walvax Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Price target decreased by 28% to CN¥13.00

Consensus revenue estimates fall by 16%

Price target decreased by 11% to CN¥17.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

First quarter 2024 earnings: EPS and revenues miss analyst expectations

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Consensus revenue estimates fall by 12%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Price target decreased by 25% to CN¥25.50

Consensus revenue estimates fall by 21%

Price target decreased by 8.1% to CN¥34.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Price target increased by 19% to CN¥37.00

Price target decreased by 9.1% to CN¥30.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 16%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥32.00

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥36.00

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Consensus forecasts updated

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥48.62

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

Earnings released

New 90-day high - CN¥71.98

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin